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INTRODUCTION:  The  giant  cell  tumor,  in  which  BCL-2  gene  was expressed  only  in  its  malignant  transfor-
mation,  is a benign,  primary  skeletal  neoplasm  with  variable  biologic  aggressiveness.  The  is  of  the  giant
cell tumor.  A  coexistence  with  hereditary  multiple  exostosis  with  expression  of EXT-1  is very rare.  The
correlation  between  giant  cell  tumor  in  hereditary  multiple  exostosis  is  still not  clearly  determined.
PRESENTATION  OF  CASE:  A 31-years-old  female  presented  with  pain  and  lump  on her  left  wrist  and
a  coexistence  of non  tender  multiple  lump  in  the  right  and  left  knee.  A wide  excision  of  the  tumor
and  reconstruction  using  non  vascularized  ﬁbular  graft  was  performed,  followed  by  histopathology  and
immunohistochemistry  of EXT-1  and  BCL-2.CL-2 gene
iant cell tumor
ereditary multiple exostosis
DISCUSSION:  In this  case,  the tumor  showed  negative  BCL-2  and  positive  EXT-1  gene  expression.  Giant
cell  tumor  and  hereditary  multiple  exostosis  also  demonstrated  associations  of chromosomes  11  with  a
different  pathological  process.
CONCLUSION:  Giant  cell  tumor  in  hereditary  multiple  exostosis  revealed  positive EXT-1  without  BCL-2
expression.  It  still  need  more  investigation  to conﬁrm  the relationship  between  these  tumors.
©  2016  The  Author(s).  Published  by  Elsevier  Ltd  on behalf  of IJS  Publishing  Group  Ltd.  This  is  an  open
he  CCaccess  article  under  t
. Introduction
Giant cell tumor (GCT) is a locally aggressive neoplasm. It often
haracterized by osteolytic destruction at the end of a long bone and
arge multinuclear cells in its histologic appearance. It is benign in
ature and known to be able to both recur and transform into malig-
ancy [1–3]. The malignant subtype of GCT is usually expressed
ome genes like the B-Cell Lymphoma 2 (BCL-2) gene [4]. The GCT
as rarely found in coexistence with other benign lesion such as
ereditary multiple exostosis (HME) [5,6]. The reason behind that
oexistence is still unclear, whether caused by either a transforma-
ion of HME  or only considered as two separated lesions. Hereditary
ultiple exostosis is an autosomal dominant condition which char-
cterized by the development of multiple exostosis and possess
nterfamilial and intrafamilial phenotypical variability in severity,
ize, and number of lesions. This HME  lesions are primarily caused
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by the presence of Exostosin-1 (EXT-1) gene that occur in approxi-
mately 90% of cases [7]. The aim of this report is to identify the BCL-2
and EXT-1 gene in GCT with coexistence of HME. It also served as a
preliminary research to prove that the GCT with the expression of
EXT-1 and BCL-2 in patients with HME  tend to be more aggressive
with high local recurrence and worse prognosis.
2. Presentation of case
A 31-years-old female presented with pain and lump on her left
wrist since 4 months ago. Physical examination revealed a lump
located on left wrist. The size of the lump clinically was 5 cm by
6 cm with shiny skin, clear border, ﬁrm in consistency, and ﬁxed to
the bone (Fig. 1a). Her wrist extension and ﬂexion was limited to
10◦ of ﬂexion and 5◦ of extension due to pain and mass. On the right
and left knees, we found non-tender multiple lumps (Fig. 1b). The
x ray of left wrist revealed osteolytic lesion with some geographic
patterns (Fig. 1c).
She had wide surgical excision of the tumor which extended
to the wrist joint and 3 cm upper the tumor followed by recon-
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 3. The histopathological result.Fig. 1. Clinical and X-ray Findings.truction using non vascularized ﬁbular graft. Proximal ﬁbular graft
as harvested, including the head of left ﬁbula. We  found multiple
ony masses with clinical characteristics of multiple exostosis on
Fig. 2. Post wide excision and reconthe proximal site of ﬁbular graft (Fig. 2a). The excised part of the
radius has replaced with non-vascularized ﬁbular graft, then ﬁxed
with plate and screws. The distal part of the graft was  transﬁxed
with Kirschner wire (Fig. 2d).
Histopathology and immunochemistry examination of EXT-1
and BCL-2 revealed some important ﬁndings. Histopathological
ﬁnding revealed GCT with an eosinophilic cytoplasm, round ovals
nucleus, vesicular chromatin with small nucleus prominent, and a
slight mitosis (Fig. 3). Immunochemistry ﬁnding revealed existence
of EXT-1 but no existence of BCL-2 (Fig. 4).
Mayo Wrist score was used to evaluate her functional outcome
two years post operation. The result is good with total score 90. The
patient feels no pain, already returned to regular activities, range
of motion return to 75–99% and the grip strength is 100% (Fig. 2e).
struction using ﬁbular graft.
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. Discussion
The case presented a GCT of the left wrist with another lesion of
ME  on the right and left knee. This case was very rare because
e were not able to ﬁnd more cases in the literature matching
his coexistence. There were only two cases reported in the last
en years. The ﬁrst one was reported by Heybeli et al. (2002)
entioning a coexistence of giant cell tumor over the left leg,
ara-articular osteochondroma over the left hip and an idiopathic
hrombocytopenic purpura (ITP) [5]. A curettage of GCT lesion was
erformed, followed by washing out the remainder with hot saline,
hen ﬁlled with autogenous iliac bone graft and cement. Further-
ore, proximal femoral resection and prosthetic reconstruction
ere performed on her hip. The histopathological examination
evealed a GCT of bone. Rodriguez-Franco et al. (2015) has reported
 case of GCT of proximal tibia in patient with history of multi-
le osteochondromatosis [6]. The tumor was resected, a skeletal
econstruction with GMRS prosthesis was performed, followed
y soft tissue reconstruction with rotation ﬂap. Histopathological
xamination revealed GCT with area of ﬁbrohistiocytic pattern and
omponent of aneurysmal bone cyst. The report also suggested a
ositive genetic polymorphism in the EXT-2 gene [6].
In this case, we suspected the existence of two tumors in one
atient. The immunohistochemistry examination was  performed
o assess gene proﬁle in both lesions. There was revealed a pos-
tive expression of EXT-1 gene and negative expression of BCL-2
ene from GCT mass of left wrist. The cells giving positive reactiony result (EXT-1 and BCL-2).
of anti-EXT-1 with B chomogen method (Fig. 4a and b). Positive
reaction was  pointed by blue arrow, on the other hand, negative
reaction was  represented by red arrow. There was observed some
cells giving negative reaction to BCL-2. Positive control showed
coloration on nucleus and cytoplasm, whereas no coloration on
nucleus and cytoplasm was found on negative as seen on Fig. 4c
and d, respectively.
Currently, EXT-1 gene has considered as an important causative
factor in hereditary multiple exostosis [8–10]. Hereditary multiple
exostosis is genetically heterogeneous with three loci on chromo-
somes 8q24.1, 11p13, and 19q. The ﬁrst EXT-1 locus that located
on chromosome 8 (8q24.1) was  discovered by Cook in 1993, which
also linked with chromosome 11q24. The distal end of 8q locus
is responsible for the formation of HME  and was identiﬁed as the
EXT-1. Later on, a new gene on chromosome 11 (11p11-13) was
identiﬁed as a locus for HME  and named EXT-2. A third locus on
chromosome 19p, suspected of causing HME  was named EXT-3, but
it is considered to be a minor contributor to the actual formation
of HME  [10]. Most of the EXT-1 and EXT-2 genes (80%) prompt to
mutation by nonsense, frameshift or splice-site mutations leading
to premature termination of the EXT proteins [11].
Giant cell tumor of the bone is a benign, primary skeletal neo-
plasm with variable biologic aggressiveness that demonstrates
telomeric associations of chromosomes 11, 16, 19, 20, and 21,
reduction of telomere length, marker chromosomes, double min-
utes, chromosome fragments, ring chromosomes, and polyploidy
[12]. Some gene that expressed in GCT such as iP53, H-ras, C-myc,
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MP-9, MIB-1 and BCL-2 had important rules for malignant trans-
ormation [13] . The presence of EXT-1 gene in GCT was rare as seen
n this case.
We have also performed immunohistochemistry of BCL-2 for
nding the apoptosis process in the tumor lesions. BCL-2 is an
nti-apoptosis protein whose overexpression contributes to the
ncontrollable proliferation of gliomas and other neoplasm’s [14].
CL-2 is a human proto-oncogene located on chromosome 18q21.3.
his gene was discovered as the translocate locus in B-cell lym-
homas. It encodes an integral membrane protein (25 kDa protein),
ainly localized to inner mitochondrial membrane, endoplasmic
eticulum and nuclear envelope. This gene was preventing cells
rom undergoing apoptosis. The BCL-2 overexpression increases
ifespan of B cells, maintains memory B cells, plasma cells and
eurons by prolonging life span without cell division. It also may
articipates in ion channel formation and alteration of membrane
ermeability that necessary for initiation of apoptosis. A non-
hosphorylated BCL-2 inhibits apoptosis [14].
Khooei et al. (2010) in their study reported a higher value of
CL-2 in malignant subtype of GCT [4]. This implies that malig-
ant transformation could trigger GCT cells to express this marker
ore frequently, thus, it could be regarded as an indicator for
alignant transformation and unfavorable clinical course. Pammer
t al. (1998) studied expression of regulatory apoptotic proteins in
eripheral giant cell lesions containing osteoclast-like giant cells
hat showing only weak positivity for BCL-2 [15]. In this case the
CL-2 result is negative, revealing that the giant cell tumor was  not
ransformed into malignant.
Based on the results of this study, GCT characterized as benign
ggressive with negative BCL-2 gene expression and showed sim-
larity with HME by a positive EXT-1 gene expression. The GCT
nd HME also demonstrated associations of chromosomes 11 with
ifferent pathological process [12].
A data based on ontology between HME  and GCT assuming that
CT may  arise from a transformation of HME. Further investiga-
[
[etween GCT and HME.
tion is needed to conﬁrm the relationship between these tumors
(Fig. 5)[16].
4. Conclusion
Giant cell tumor in hereditary multiple exostosis revealed posi-
tive EXT-1 without BCL-2 expression. In this case, this coexistence
revealed a probability of GCT that arised from HME  but did not
showed malignant transformation. Further advanced researches
are needed to conﬁrm the association between HME  and GCT
lesion.
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